Skip to main content
. 2019 Jan 24;24(7):893–900. doi: 10.1634/theoncologist.2018-0407

Figure 3.

image

Prognosis based on subtype classification. (A): PFS in HER2‐enriched versus non‐HER2‐enriched subgroups. (B): PFS in luminal (including normal‐like) versus nonluminal subgroups.

Abbreviations: CI, confidence interval; HER2, human epidermal growth factor receptor 2; PFS, progression‐free survival.